Therapy Detail

Therapy Name Lenalidomide
Therapy Description

Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Lenalidomide Revlimid IMiD-1 Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown multiple myeloma not applicable Lenalidomide Phase III Actionable In a Phase III trial, Revlimid (lenalidomide) maintenance treatment after stem cell transplant resulted in improved overall survival and progression free survival in patients with multiple myeloma (J Clin Oncol 35, 2017 (suppl; abstr 8037)). detail...
IKZF1 wild-type multiple myeloma sensitive Lenalidomide Preclinical Actionable In a preclinical study, Revlimid (lenalidomide) treatment resulted in IKZF1 degradation and decreased proliferation of multiple myeloma cells in culture (PMID: 24292625). 24292625
Unknown unknown mantle cell lymphoma not applicable Lenalidomide FDA approved Actionable In a Phase II trial (EMERGE) that supported FDA approval, Revlimid (lenalidomide) treatment resulted in an objective response rate of 28% (37/134) with rapid time to response (2.2 months), a median duration of response of 16.6 months, a median progression-free survival of 4.0 months, and a median overall survival of 19.0 months in patients with mantle cell lymphoma who relapsed or progressed after or were refractory to Velcade (bortezomib) (PMID: 24002500; NCT00737529). 24002500
Clinical Trial Phase Therapies Title Recruitment Status
NCT02579863 Phase III Pembrolizumab Dexamethasone Lenalidomide Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) Active, not recruiting
NCT02331368 Phase II Lenalidomide Melphalan Pembrolizumab Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma Completed
NCT01954784 Phase I Bortezomib + Cyclosporine + Mycophenolate mofetil Lenalidomide Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma Terminated
NCT02589145 Phase Ib/II Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype Terminated
NCT01863550 Phase III Dexamethasone Lenalidomide Carfilzomib Bortezomib Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Recruiting
NCT01604031 Phase Ib/II Lenalidomide Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide Terminated
NCT01459211 Phase II Dexamethasone Lenalidomide Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) Completed
NCT03004287 Phase II Melphalan Carfilzomib Cisplatin Cyclophosphamide Lenalidomide Dexamethasone Daratumumab Bortezomib Etoposide Doxorubicin Thalidomide 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy Recruiting
NCT02126553 Phase II Lenalidomide Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission Recruiting
NCT01556776 Phase III Lenalidomide A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy Active, not recruiting
NCT01415752 Phase II Bortezomib Bendamustine Rituximab Lenalidomide Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma Recruiting
NCT03506802 Phase I Filgrastim + Plerixafor Lenalidomide Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC Melphalan TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma Recruiting
NCT03570892 Phase III Lenalidomide Ibrutinib Carboplatin + Etoposide + Ifosfamide + Rituximab Carmustine + Cytarabine + Etoposide + Melphalan Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cyclophosphamide + Fludarabine + Tisagenlecleucel Cisplatin + Cytarabine + Dexamethasone + Rituximab Gemcitabine + Oxaliplatin + Rituximab Bendamustine + Fludarabine + Tisagenlecleucel Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA) Recruiting
NCT01216683 Phase II Bendamustine + Rituximab Bortezomib Lenalidomide Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Active, not recruiting
NCT01919086 Phase II Lenalidomide Bortezomib + Dexamethasone Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma Active, not recruiting
NCT01998971 Phase I Pomalidomide Bortezomib + Dexamethasone Melphalan Thalidomide Lenalidomide Prednisone Daratumumab Carfilzomib Diphenhydramine Montelukast A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma Active, not recruiting
NCT02431208 Phase I Lenalidomide Atezolizumab A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM) Active, not recruiting
NCT01218555 Phase I Lenalidomide Everolimus Study of Everolimus (RAD001)in Combination With Lenalidomide Completed
NCT02265510 Phase I Gemcitabine Carfilzomib Dexamethasone Lenalidomide Nab-paclitaxel Azacitidine INCB052793 Bortezomib An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies Active, not recruiting
NCT01827137 Phase I WT1 vaccine Lenalidomide Sargramostim WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation Unknown status
NCT02030483 Phase I Palbociclib Dexamethasone Lenalidomide Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma Terminated
NCT01729091 Phase Ib/II Dexamethasone Elotuzumab Filgrastim Melphalan Lenalidomide Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma Active, not recruiting